<p>Soligenix Inc. has released a corporate presentation outlining its progress in developing treatments for rare diseases and public health threats. The company highlights its late-stage pipeline, which includes HyBryte (SGX301) for cutaneous T-cell lymphoma with positive Phase 3 results and ongoing confirmatory studies. Other clinical-stage assets include SGX302 for psoriasis and SGX945 for Behçet’s disease, both with orphan designations. The presentation details significant funding from federal sources, including NIH contracts and grants, and estimates a total addressable global market potential of approximately $2 billion in annual sales across its portfolio. You can access the full presentation through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Soligenix Inc. published the original content used to generate this news brief on January 08, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here</p>

Soligenix Showcases Rare Disease Pipeline and Market Potential in New Corporate Presentation